Gene-Edited immune cells take on Hard-to-Treat cancers
Disease control
Completed
This early-phase trial tested a new treatment called CTX131 for adults with several types of advanced solid tumors that had stopped responding to standard therapies. CTX131 uses a patient's own immune cells that are edited with CRISPR technology to target a protein called CD70 on…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 13, 2026 15:58 UTC